STUDY ON THE VALUE OF SERUM GROWTH DIFFERENTIATION FACTOR-15 COMBINED WITH B-TYPE URINARY NATRIURETIC PEPTIDE PRECURSOR IN THE DIAGNOSIS AND PROGNOSIS OF HEART FAILURE

被引:1
作者
Wei, Hongxia [1 ]
Tan, Tingting [1 ]
Cheng, Li [1 ]
Li, Lei [1 ]
Song, Hongyan [1 ]
Zhang, Kui [1 ]
机构
[1] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Lab Med, Nanjing, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2020年 / 36卷 / 06期
关键词
Growth differentiation factor-15; B-type natriuretic peptide precursor; heart failure; diagnosis; prognosis assessment; GDF-15;
D O I
10.19193/0393-6384_2020_6_526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study the value of serum growth differentiation factor-15 (GDF-15) combined with B-type natriuretic peptide (NT-proBNP) in the diagnosis and prognosis of heart failure. Methods: Sixty-eight patients with heart failure from July 2017 to July 2018 were selected. The NYHA classification was divided into 40 patients with mild heart failure (NYHA class I-II) and 38 patients with severe heart failure (NYHA class III-IV). The value of GDF-15 and NT-proBNP for diagnosing heart failure was studied with an ROC curve. The prognostic value of GDF-15 and NT-proBNP in heart failure was discussed according to the outcomes of the follow-up group. Results: The serum GDF-15 and NT-proBNP levels in patients with mild heart failure and patients with severe heart failure were higher than those of the control group (P<0.01). The serum GDF-15 and NT-proBNP levels in patients with severe heart failure were higher than those with mild heart failure (P<0.01). The AUC of GDF-15 in the ROC curve was 0.885 (95% CI = 0.812-0.954), and the best diagnostic node was 916.26 ng/L, with corresponding sensitivity and specificity of 7836% and 8129%, respectively. The AUC of NT-proBNP for diagnosing heart failure was 0.912 (95% CI: 0.864-0.968), and the best diagnosis node was 1623 28 ng/L. The corresponding sensitivity and specificity were 82.16% and 89.52%, respectively. The AUC of GDF-15 + NT-proBNP for diagnosing heart failure was 0.953 (95% CI: 0.891-0.992), and its sensitivity and specificity were 89.73% and 92.14%, respectively. The value of GDF-15 combined with NT-proBNP in diagnosing heart failure was the highest. In the follow-up year, the mortality and readmission rate of the heart failure group were higher than those of the control group (P<0.01). Additionally, the GDF-15 and NT-proBNP levels in the poor prognosis group were higher than those in the patients with good prognosis (P<0.01). The AUC of GDF- 15 in the analysis of the ROC curve was 0.849 (95% CI: 0.785-0.893), and the sensitivity and specificity were 8636% and 8036%, respectively. The AUC of NT-proBNP in the treatment of heart failure was 0.801 (95% CI: 0.749-0.865), and the sensitivity and specificity were 83.69% and 7536%, respectively. The AUC of GDF-15 NT-proBNP in diagnosing heart failure was 0.897 (95% CI: 0.815-0.932), and the sensitivity and specificity were 8936% and 81.14%, respectively. Among these, the value of GDF-15 combined with NT-proBNP in evaluating the prognosis of heart failure was the highest. Conclusion: GDF-15 and NT-proBNP can be used as a test index for diagnosing heart failure and evaluating its prognosis. The value of GDF-15 and NT-proBNP in the diagnosis and prognosis of heart failure is the highest.
引用
收藏
页码:3321 / +
页数:5
相关论文
共 15 条
  • [1] [Anonymous], 2017, BIOMED RES INT, DOI [DOI 10.1155/2017/6274854, 10.1155/2017/6274854]
  • [2] Association between GDF-15 levels and changes in vascular and physical function in older patients with hypertension
    Barma, Maryam
    Khan, Faisel
    Price, Rosemary J. G.
    Donnan, Peter T.
    Messow, C. Martina
    Ford, Ian
    McConnachie, Alex
    Struthers, Allan D.
    McMurdo, Marion E. T.
    Witham, Miles D.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2017, 29 (05) : 1055 - 1059
  • [3] An exploration of the prevalence and experience of cardiac cachexia: protocol for a mixed methods cross-sectional study
    Carson, Matthew A.
    Reid, Joanne
    Hill, Loreena
    Dixon, Lana
    Donnelly, Patrick
    Slater, Paul
    Hill, Alyson
    Fitzsimons, Donna
    [J]. BMC PALLIATIVE CARE, 2019, 18 (01)
  • [4] Deng SW, 2017, J CARDIO CEREBROVASC, V15, P2294
  • [5] Updates in heart failure: what last year brought to us
    Dinatolo, Elisabetta
    Sciatti, Edoardo
    Anker, Markus S.
    Lombardi, Carlo
    Dasseni, Nicolo
    Metra, Marco
    [J]. ESC HEART FAILURE, 2018, 5 (06): : 989 - 1007
  • [6] Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure
    Duan, H. Y.
    Liu, D. M.
    Qian, P.
    Wang, S. L.
    Yan, L. J.
    Wu, J. T.
    Yang, H. T.
    Fan, X. W.
    Chu, Y. J.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 15739 - 15748
  • [7] Metabolic remodeling induced by mitokines in heart failure
    Duan, Jiahao
    Chen, Zijun
    Wu, Yeshun
    Zhu, Bin
    Yang, Ling
    Yang, Chun
    [J]. AGING-US, 2019, 11 (17): : 7307 - 7327
  • [8] Highly sensitive and specific on-site detection of serum cocaine by a low cost aptasensor
    Oueslati, Rania
    Cheng, Cheng
    Wu, Jayne
    Chen, Jiangang
    [J]. BIOSENSORS & BIOELECTRONICS, 2018, 108 : 103 - 108
  • [9] Riehle C, 2017, CIRC RES, V118, P1151
  • [10] Shi LP, 2017, CHIN MED EMERG, V26, P15